Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Clin Lung Cancer. 2015 Mar 18;16(3):165–172. doi: 10.1016/j.cllc.2015.03.001

Figure 2.

Figure 2

Panel of Non–Small-Cell Lung Cancer (NSCLC) Patient-Derived Xenograft (PDX) Models That Harbor Epidermal Growth Factor Receptor (EGFR)-Activating Mutations. Models Are Organized According to Patient Clinical Status at the Time of the Originating Biopsy. “Erlotinib Sensitive-Naive” Models Were Acquired Before Treatment With Any EGFR Inhibitor; “Primary Resistance” Models Were Derived From Tumors That Showed No Clinical Benefit From Erlotinib; “Acquired Resistance” Models Were Derived From Tumors That Initially Responded to Erlotinib But Had Progressed at the Time of Biopsy. Models Were Also Subdivided According To Those With EGFR Gene Amplification (Upper Circle). Additional Information Is Provided in Each Box, Indicating Oncogenic Abnormalities of Interest. Abbreviations: AMP = amplification; mut = mutation